PRTO Proteon Therapeutics Inc.

1.75
+0.10  (6%)
Previous Close 1.65
Open 1.65
Price To book 1.05
Market Cap 30833982
Shares 17,619,418
Volume 112,261
Short Ratio 2.58
Av. Daily Volume 43,062

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released December 13, 2016 - primary endpoint not met.
Vonapanitase (PRT-201) PATENCY-1
Chronic kidney disease (CKD) patients undergoing surgical placement of an arteriovenous fistula (AVF)
Phase 3 enrollment to be completed 1Q 2018. Data due 1Q 2019.
Vonapanitase (PRT-201) PATENCY-2
Chronic kidney disease (CKD) patients undergoing surgical placement of an arteriovenous fistula (AVF)